Munther Abosaooda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Munther Abosaooda has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Qayssar Joudah Fadheel
Department of Pharmacology and Toxicology, College of Pharmacy, University of Babylon, Babylon, Iraq
2 shared publications
Latest Publications
- 30 December 2025
- Published by ALUNA in Wiadomości Lekarskie
- No. 12,p. 2648-2660
Modulation of Renal FOXO3 Gene Expression by Urolithin A in a Rat Model of Renal Ischemia-Reperfusion Injury
Aim: Background: Ischemia/reperfusion renal injury (IRI), which is predominantly brought on by inflammation and oxidative stress, is the main cause of acute kidney damage. Aims: This work uses a male Wistar Albino rat model of experimentally induced renal ischemia-reperfusion injury (IRI) to examine the nephroprotective potential of Urolithin A. Material and methods: Materials and methods: Twenty-eight rats (N=7) were randomly assigned to four groups: DMSO pre-injection as a vehicle, bilateral renal IRI for 30 minutes followed by two hours of reperfusion as a control, sham (laparotomy without IRI), and treatment (Urolithin A pre-injection for three days). ELISA and histological analysis were used to assess biomarkers of kidney injury, oxidative stress, inflammation, and apoptosis. Results: Results: While GSH levels were enhanced, Urolithin A therapy primarily decreased TNF-α, IL-1β, MDA, Caspase-3, and KIM-1 levels. Furthermore, the group treated with Urolithin A showed a substantial downregulation of FOXO3 expression. Histopathological results verified that the therapy group had less kidney damage. Conclusions: Conclusion: These findings suggest that Urolithin A produces nephroprotective effects against IRI via modulating oxidative stress, inflammation, and apoptosis, particularly through the control of FOXO3. This study suggests that Urolithin A is a good treatment candidate for renal IRI control.
- 30 December 2025
- Published by ALUNA in Wiadomości Lekarskie
- No. 12,p. 2648-2660
Modulation of Renal FOXO3 Gene Expression by Urolithin A in a Rat Model of Renal Ischemia-Reperfusion Injury
Aim: Background: Ischemia/reperfusion renal injury (IRI), which is predominantly brought on by inflammation and oxidative stress, is the main cause of acute kidney damage. Aims: This work uses a male Wistar Albino rat model of experimentally induced renal ischemia-reperfusion injury (IRI) to examine the nephroprotective potential of Urolithin A. Material and methods: Materials and methods: Twenty-eight rats (N=7) were randomly assigned to four groups: DMSO pre-injection as a vehicle, bilateral renal IRI for 30 minutes followed by two hours of reperfusion as a control, sham (laparotomy without IRI), and treatment (Urolithin A pre-injection for three days). ELISA and histological analysis were used to assess biomarkers of kidney injury, oxidative stress, inflammation, and apoptosis. Results: Results: While GSH levels were enhanced, Urolithin A therapy primarily decreased TNF-α, IL-1β, MDA, Caspase-3, and KIM-1 levels. Furthermore, the group treated with Urolithin A showed a substantial downregulation of FOXO3 expression. Histopathological results verified that the therapy group had less kidney damage. Conclusions: Conclusion: These findings suggest that Urolithin A produces nephroprotective effects against IRI via modulating oxidative stress, inflammation, and apoptosis, particularly through the control of FOXO3. This study suggests that Urolithin A is a good treatment candidate for renal IRI control.
- 30 October 2025
- Published by ALUNA in Wiadomości Lekarskie
- Vol. 2025 (10) , 2034-2044
Carbenoxolone Attenuates Renal Ischemia-Reperfusion Injury in Rats by Modulating Inflammatory Cytokines, Oxidative Stress Markers, and Apoptotic Pathways
Aim: Background: Ischemia/reperfusion injury (IRI) is a major cause of kidney damage, primarily driven by oxidative stress and inflammation. Aims: This study investigates the protective effects of Carbenoxolone (Cbx) in attenuating renal injury through the modulation of the FOXO3 gene. Material and methods: Materials and methods: Twenty-eight adult male Wistar Albino rats were randomly divided into four groups (N=7): Sham (laparotomy without ischemia), Control (bilateral renal ischemia for 30 min followed by 2 h reperfusion), Vehicle (DMSO injection prior to IRI), and Carbenoxolone-treated (Cbx injection three days before IRI). Results: Results: Tissue levels of TNF-α, IL-1β, MDA, Caspase-3, and KIM-1 were significantly elevated in the control and vehicle groups, while GSH levels were reduced. Cbx treatment significantly decreased TNF-α, IL-1β, MDA, Caspase-3, and KIM-1 while increasing GSH levels, indicating enhanced antioxidant defense. FOXO3 expression was notably lower in the Cbx group compared to the control and vehicle groups. Histopathological analysis further confirmed reduced renal damage in Cbx-treated rats. These findings suggest that Cbx exerts renoprotective effects by mitigating oxidative stress, inflammation, and apoptosis. Conclusions: Conclusion: Carbenoxolone significantly reduces RIRI-induced kidney damage, demonstrating its potential as a therapeutic agent for renal ischemic injuries.
- 30 October 2025
- Published by ALUNA in Wiadomości Lekarskie
- Vol. 2025 (10) , 2034-2044
Carbenoxolone Attenuates Renal Ischemia-Reperfusion Injury in Rats by Modulating Inflammatory Cytokines, Oxidative Stress Markers, and Apoptotic Pathways
Aim: Background: Ischemia/reperfusion injury (IRI) is a major cause of kidney damage, primarily driven by oxidative stress and inflammation. Aims: This study investigates the protective effects of Carbenoxolone (Cbx) in attenuating renal injury through the modulation of the FOXO3 gene. Material and methods: Materials and methods: Twenty-eight adult male Wistar Albino rats were randomly divided into four groups (N=7): Sham (laparotomy without ischemia), Control (bilateral renal ischemia for 30 min followed by 2 h reperfusion), Vehicle (DMSO injection prior to IRI), and Carbenoxolone-treated (Cbx injection three days before IRI). Results: Results: Tissue levels of TNF-α, IL-1β, MDA, Caspase-3, and KIM-1 were significantly elevated in the control and vehicle groups, while GSH levels were reduced. Cbx treatment significantly decreased TNF-α, IL-1β, MDA, Caspase-3, and KIM-1 while increasing GSH levels, indicating enhanced antioxidant defense. FOXO3 expression was notably lower in the Cbx group compared to the control and vehicle groups. Histopathological analysis further confirmed reduced renal damage in Cbx-treated rats. These findings suggest that Cbx exerts renoprotective effects by mitigating oxidative stress, inflammation, and apoptosis. Conclusions: Conclusion: Carbenoxolone significantly reduces RIRI-induced kidney damage, demonstrating its potential as a therapeutic agent for renal ischemic injuries.